Value of information analyses of economic randomized controlled trials: The treatment of intermittent claudication

Value in Health

Volumn 13, Issue 2, 2010, Pages 242-250

  Koerkamp, Bas Groot ^a,b   Spronk, Sandra ^a   Stijnen, Theo ^c   Hunink, M G Myriam ^a,d  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Cost effectiveness analysis; Intermittent claudication; Randomized controlled trial; Value of information analysis

Indexed keywords

ARTICLE; CLINICAL TRIAL; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; ENDOVASCULAR SURGERY; EXERCISE; FUNDING; HEALTH CARE COST; HUMAN; INTERMITTENT CLAUDICATION; METHODOLOGY; MONEY; MONTE CARLO METHOD; PARAMETER; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; REVASCULARIZATION; SAMPLE SIZE; VALUE OF INFORMATION ANALYSIS;

EID: 77149156284     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1111/j.1524-4733.2009.00656.x     Document Type: Article

References (28)

1. Spronk S, Bosch J, den Hoed P, et al. Cost-effectiveness of endovascular revascularization compared to supervised hospital-based exercise training in patients with intermittent claudication: a randomized controlled trial. J Vasc Surg 2008 48 : 1472 1480.
2. Claxton K, Sculpher M, Drummond M. A rational framework for decision making by the National Institute for Clinical Excellence (NICE). Lancet 2002 360 : 711 715.
3. Claxton K, Ginnelly L, Sculpher M, et al. A pilot study on the use of decision theory and value of information analysis as part of the NHS Health Technology Assessment programme. Health Technol Assess 2004 8 : 1 103, iii.
4. Yokota F, Thompson KM. Value of information literature analysis: a review of applications in health risk management. Med Decis Making 2004 24 : 287 298. (Pubitemid 38656313)
5. Ramsey S, Willke R, Briggs A, et al. Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report. Value Health 2005 8 : 521 533.
6. Ades AE, Lu G, Claxton K. Expected value of sample information calculations in medical decision modeling. Med Decis Making 2004 24 : 207 227.
7. R. 1.7.1 ed: The R Development Core Team. 2003.
8. Microsoft Corporation. Excel. Redmond, WA : 2002.
9. Inter-Society Consensus for the Management of PAD (TASC II) Working Group. Available from: http://www.tasc-2-pad.org [Accessed June 26, 2009 S, Bosch J, den Hoed P, et al. Intermittent claudication: clinical effectiveness of endovascular revascularization versus supervised hospital-based exercise training - randomized controlled trial. Radiology 2009 250 : 586 595.
10. de Vries SO, Visser K, de Vries JA, et al. Intermittent claudication: cost-effectiveness of revascularization versus exercise therapy. Radiology 2002 222 : 25 36.
11. Murphy TP, Ariaratnam NS, Carney WI Jr., et al. Aortoiliac insufficiency: long-term experience with stent placement for treatment. Radiology 2004 231 : 243 249.
12. Busschbach J. Dutch scoring algorithm for EuroQol-5D. Available from: http://www.xs4all.nl/∼jannetvb/busschbach/faq-qoL&euroqol.htm [Accessed September 23, 2009 AA, Mullahy J. Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis. Med Decis Making 1998 18 (2 Suppl. S68 80.
13. Council for Public Health and Health Care. Zinnige en Duurzame Zorg. Zoetermeer : Raad voor de Volksgezondheid en Zorg, 2006. Available in English from: http://www.rvz.net/cgi-bin/rvz-p.pl?id=12 [Accessed September 23, 2009 B, Tibshirani RJ. An Introduction to the Bootstrap. New York : Chapman & Hall, 1993.
14. Claxton K, Posnett J. An economic approach to clinical trial design and research priority-setting. Health Econ 1996 5 : 513 524.
15. Willan AR, Pinto EM. The value of information and optimal clinical trial design. Stat Med 2005 24 : 1791 1806.
16. Anderson TW. An Introduction to Multivariate Statistical Analysis (2nd ed.). Hoboken, NJ : Wiley-Interscience, 1984.
17. Claxton K, Thompson KM. A dynamic programming approach to the efficient design of clinical trials. J Health Econ 2001 20 : 797 822.
18. Campbell H, Briggs A, Buxton M, et al. The credibility of health economic models for health policy decision-making: the case of population screening for abdominal aortic aneurysm. J Health Serv Res Policy 2007 12 : 11 17.
19. Ramsey SD, Berry K, Etzioni R, et al. Cost effectiveness of lung-volume-reduction surgery for patients with severe emphysema. N Engl J Med 2003 348 : 2092 2102.
20. Grundy PM, Healy MJR, Rees DH. Economic choice of the amount of experimentation. J R Stat Soc [Ser A] 1956 18 : 32 48.
21. Raiffa H, Schlaifer RO. Applied Statistical Decision Theory. Cambridge, MA : Division of Research, Graduate School of Business Administration, Harvard University, 1961.
22. Detsky AS. Are clinical trials a cost-effective investment? JAMA 1989 262 : 1795 1800.
23. Detsky AS. Using cost-effectiveness analysis to improve the efficiency of allocating funds to clinical trials. Stat Med 1990 9 : 173 184.
24. Willan AR. Clinical decision making and the expected value of information. Clin Trials 2007 4 : 279 285.
25. Freiman JA, Chalmers TC, Smith HJ, Kuebler RR. The importance of beta, the type II error and sample size in the design and interpretation of the randomized controlled trial. Survey of 71 "negative" trials. N Engl J Med 1978 299 : 690 694.
26. Altman DG, Bland JM. Absence of evidence is not evidence of absence. Br Med J 1995 311 : 485.
27. Phillips CV. The economics of "more research is needed Int J Epidemiol 2001 30 : 771 776.
28. Groot Koerkamp B, Nikken JJ, Oei EH, et al. Value of information analysis used to determine the necessity of additional research: MR imaging in acute knee trauma as an example. Radiology 2008 246 : 420 425.